Product Images Perindopril Erbumine

This is a graph showing the Time to First Occurrence of Primary Endpoint with logrank p=0.0003 for Placebo and Perindopril. The primary endpoint being the cardiovascular mortality, nonfatal MI, or cardiac arrest. The x-axis is time in years and the y-axis is the proportion of people who had the primary endpoint. The graph shows that Perindopril has a lower proportion of people with the primary endpoint compared to the Placebo. The number of patients at risk is also provided for each group at different times.*

Figure 2. Beneficial Effect of Perindopril Treatment on Primary Endpoint in Predefined Subgroups is a graph that shows the number of primary events (k) in patients with different characteristics who were treated with either perindopril or placebo. Subgroups include gender, age, previous medical conditions, and medication usage. The graph demonstrates that perindopril treatment had a favorable effect on the primary endpoint in all subgroups compared to the placebo.*